Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy by Tomson, Torbjörn et al.
Journal Identification = EPD Article Identification = 1105 Date: December 19, 2019 Time: 11:45 am
d
o
i:1
0.
16
84
/e
p
d
.2
01
9.
11
05
Epileptic Disord, Vol. 21, No. 6, December 2019 497
Correspondence:
Torbjörn Tomson
Department of Clinical Neuroscience,
Karolinska Institutet,
Department of Neurology,
Karolinska University Hospital,
SE 171 76 Stockholm, Sweden
<torbjorn.tomson@sll.se>
ILAE report
Epileptic Disord 2019; 21 (6): 497-517
Management of epilepsy in
pregnancy: a report from the
International League Against
Epilepsy Task Force on Women
and Pregnancy
Torbjörn Tomson 1, Dina Battino 2, Rebecca Bromley 3,
Silvia Kochen 4, Kimford Meador 5, Page Pennell 6,
Sanjeev V. Thomas 7
1 Department of Clinical Neuroscience Karolinska Institutet, and Department of
Neurology, Karolinska University Hospital, Stockholm, Sweden
2 Epilepsy Center, Department of Neurophysiology and Experimental Epileptology,
Fondazione IRCCS Istituto Neurologico CARLO BESTA, Milan, Italy
3 Division of Evolution and Genomic Science, School of Biological Sciences, Faculty of
Biology, Medicine and Health, University of Manchester, Manchester Academic Health
Science Centre, Manchester, UK; Royal Manchester Children’s Hospital, Central
Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health
Science Centre, Manchester, UK
4 Epilepsy Center, ENyS, CONICET, Hosp. El Cruce, Hosp. R. Mejía, Univ Buenos Aires,
Argentina
5 Department of Neurology & Neurological Sciences, Stanford University, Palo Alto,
CA, USA
6 Department of Neurology, Harvard Medical School, Divisions of Epilepsy and
Women’s Health, Brigham and Women’s Hospital, Boston, MA, USA
7 Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences and
Technology, Trivandrum, Kerala State, India
Received July 02, 2019; Accepted October 05, 2019
ABSTRACT – The risks associated with use of antiepileptic drugs during
pregnancy are a major concern for all women with epilepsy with childbear-
ing potential. These risks have to be balanced against foetal and maternal
risks associated with uncontrolled seizures. This report from the Interna-
tional League Against Epilepsy Task Force on Women and Pregnancy aims to
provide a summary of relevant data on these risks as a basis for expert opin-
ion recommendations for the management of epilepsy in pregnancy. The
report reviews data on maternal and foetal risks associated with seizures
as well as teratogenic risks associated with antiepileptic drug exposure,
including effects on intrauterine growth, major congenital malformations,
and developmental and behavioural outcomes. The impact of pregnancy
on seizure control and on the pharmacokinetics of antiepileptic drugs are
also discussed. This information is used to discuss how treatment may be
optimized before conception and further managed during pregnancy.
Key words: epilepsy, pregnancy, antiepileptic drugs, foetal risks,
teratogenesis
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t is estimated that, globally, approximately 15 million
omen with epilepsy are of childbearing age. Most of
hese women are in need of effective and safe treat-
ent for their epilepsy also during pregnancy. For
hem, as well as for their partners, the possible risks
o the unborn induced by use of antiepileptic drugs
AEDs) during pregnancy is a major concern. While
t is important to understand that the vast majority
f women with epilepsy can have uneventful preg-
ancies and give birth to perfectly healthy children,
here are also foetal risks associated with treatment.
hese risks include negative effects on foetal growth,
ncreased risks of major congenital malformations
MCM), as well as adverse effects on neurocognitive
nd behavioural development. However, uncontrolled
aternal seizures can also be harmful not only to the
regnant woman but also to the foetus. The aim of
his article is to present the facts on these risks and,
ost importantly, based on this, to provide practi-98
al recommendations on how risks can be balanced
nd reduced and suggest how epilepsy may be man-
ged before and during pregnancy and after delivery
n order to optimize outcomes. The recommendations
re based on review of the relevant literature carried
ut by the International League Against Epilepsy (ILAE)
ask Force on Women and Pregnancy. The search strat-
gy and criteria for selection are summarized in Box 1.
Box 1. Search strategy.
References for this review were identified from
the authors’ files and from a PubMed search
(from 2009 through August 2019) using at least
one of the following terms (by searching as
text words): “epilep*”, “seizure*”, “antiepileptic*”,
“anti-epileptic*”, “anticonvuls*”, “anti-convuls*”,
“barbit*, and specific drug names. Publications
found were limited to those retrieved by search-
ing as text word at least one of the follow-
ing terms: “pregnan*”, “maternal”, “mother”,
“parent*”, “fetal”, “foetal”, “fetus”, “foetus”,
“feto*”, “foeto*”, “defects”, “embryopat*”, (“con-
genital” AND “malformation*”), (“congenital” AND
“abnormalit*”), (“congenital” AND “anomal*”),
“offspring*”, “utero”, “terato*”, “intrauterine”,
“intra-uterine”, (“before” AND “birth”), “infant”,
“prenatal”, “pre-natal”, “obstetric*, “delivery”,
(“birth” AND “outcome*”), (“children” AND “of”
AND “women”), and (“pregnancy” AND “cognitive
development” OR “development” OR “neurode-
velopment” OR “IQ”). Eligible articles were further
limited by excluding all the articles found by enter-
ing in the medical subject headings field, the
expression (“animals” NOT “human”). Only papers
published in English were reviewed. The final ref-
erence list was generated on the basis of originality
and relevance to the broad scope of this review.
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mphasis was focused on publications in the last 10
ears, i.e. after the publication of the guidelines from
he American Epilepsy Society (Harden et al., 2009a,
009b). Recommendations should be considered as
n expert opinion rather than evidence-based guide-
ines. This approach was taken due to limitations in the
resent evidence base, which leave clinicians and their
atients without adequate information. This report is
ntended to fill this gap, at least in part.
he manuscript is addressing the following learning
bjective of the ILAE curriculum (Blümcke et al., 2019):
Provide guidance regarding pregnancy, including ter-
togenicity of the various antiepileptic drugs”.
o further illustrate the discussion, four brief case
ignettes are presented and discussed at the end of
he article.
aternal and foetal risks associated
ith seizures
he risk of seizures during pregnancy and the con-
equences that they might have on the developing
oetus as well as the mother are fundamental reasons
or the use of AEDs, and this should be no different for
pileptic women with childbearing potential as they
ay become pregnant (Sveberg et al., 2015).
ocal seizures that do not evolve to bilateral tonic-
lonic seizures are unlikely to have a major impact
n the foetus, although there are a few case reports
ndicating brief foetal distress, expressed as deceler-
tion of foetal heart rate for 2.5-3.5 minutes, during
ocal seizures with impaired awareness (Nei et al.,
998; Sahoo and Klein, 2005). Generalized tonic-clonic
eizures (GTCS), including focal to bilateral tonic-
lonic seizures according to the current classification
Fisher et al., 2017), are associated with hypoxia and lac-
ic acidosis, which during pregnancy are transferred
o the foetus through the placenta and may lead to
sphyxia (Hiilesmaa and Teramo, 2013). Seizure-related
alls can also cause blunt trauma to the uterus and thus
ffect the foetus.
nation-wide register-based study from Taiwan found
n association between the occurrence of seizures of
ll types during pregnancy and small foetal size for
estational age, moreover, seizures during pregnancy
ere more likely to be associated with preterm deliv-
ry and lower birth weight (Chen et al., 2009). In this
tudy, occurrence of seizures was defined as those inEpileptic Disord, Vol. 21, No. 6, December 2019
omen being hospitalized or treated in the emergency
epartment for epilepsy during pregnancy, and no dis-
inction was made between different seizure types. A
maller hospital-based retrospective study from Nor-
ay found no differences in obstetrical complications
etween women with seizures during the last five
ears, based on medical records (type of seizures not
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pecified), and those without (Borthen et al., 2011).
owever, differences in methodology make it difficult
o compare between the results of these two studies.
here are no indications of an association between
aternal seizures and risk of MCM, but one retrospec-
ive study has indicated lower verbal IQ in children
f mothers with five or more GTCS during pregnancy
Adab et al., 2004). The retrospective study design,
owever, precludes definitive conclusions, and this
bservation has not been confirmed in prospective
tudies (Meador et al., 2013; Baker et al., 2015), although
hese were not designed to address the question of
ossible impact of maternal GTCS during pregnancy
n the child’s neurodevelopment.
pilepsy and uncontrolled seizures are also associated
ith maternal risks. Up to a 10-fold increased risk of
aternal mortality (Edey et al., 2014) or mortality during
ospitalised delivery (MacDonald et al., 2015) has been
eported for women with epilepsy. When the causes of
eath were analysed, the majority were seizure related
nd most due to sudden unexpected death in epilepsy
SUDEP) (Edey et al., 2014).
pilepsy is not considered as a reason for Caesarean
elivery, unless a seizure occurs during labour, making
he patient unable to cooperate (Donaldson, 2002).
• Generalized tonic-clonic seizures are associated
with risks to the foetus as well as to the pregnant
woman.
• Other seizures are probably less harmful, but may
be associated with injury, intrauterine growth retar-
dation and premature delivery.
eratogenic risks
ffects of antiepileptic drugs on intrauterine
rowth
he possibility that AED use during pregnancy is
ssociated with offspring that are small for gestational
ge (SGA) and have small head circumference has
een discussed for many years, mainly based on
utcomes of selected cohorts of pregnant women
ith epilepsy (Harden et al., 2009b). Particular interest
as been paid to the risk of microcephaly as this could
e associated with functional deficits. SGA newborns
re at risk of stillbirth and other long-term sequelae.
arlier hospital-based cohort studies (Battino et al.,
999; Hvas et al., 2000) as well as population-basedpileptic Disord, Vol. 21, No. 6, December 2019
egister studies (Wide et al., 2000a; Almgren et al.,
009; Veiby et al., 2009) have indicated an increased
isk of small head circumference among children
xposed to AED polytherapy or monotherapy with
rimidone, phenobarbital (Hiilesmaa et al., 1981;
attino et al., 1999), carbamazepine (Hiilesmaa et al.,
a
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981; Wide et al., 2000a; Almgren et al., 2009; Veiby et
l., 2009) or valproate (Wide et al., 2000a). Although
hese studies report smaller head circumference
mong those exposed, they have not shown increased
ates of microcephaly. The prospective NEAD study
ound increased rates of microcephaly (defined
s <3rd percentile) with carbamazepine and val-
roate, but normalization by two years of age
Pennell et al., 2012).
or obvious reasons, the impact of the newer-
eneration AEDs was not assessed in the earlier
tudies. However, a more recent population-based
tudy from Norway reported that, in general, chil-
ren exposed to AEDs had a moderate risk of growth
estriction. However, compared to children of healthy
others, those exposed to topiramate had a consid-
rable risk of microcephaly (11.4% vs. 2.4 %; odds
atio [OR]: 4.8) and SGA (24.4 % vs. 8.9 %; OR: 3.1)
Veiby et al., 2014). Increased risk of microcephaly
defined as head circumference <2.5th percentile),
lthough to a lesser extent, was also reported to be
ssociated with carbamazepine (OR: 2.0) and AED poly-
herapy (OR: 2.0). The same study found a significantly
ncreased risk for SGA with carbamazepine (OR: 1.4)
nd AED polytherapy (OR: 1.6). A Danish population-
ased study confirmed a more than two-fold increased
isk of SGA with topiramate exposure, and a less,
ut significantly increased, risk associated with val-
roate and carbamazepine (Kilic et al., 2014). Based
n a recent population-based Swedish register study,
elative to lamotrigine exposure, infants exposed to
arbamazepine and valproic acid had head circumfer-
nce that was smaller by 0.2 SDs, those exposed to
evetiracetam had smaller head circumference by 0.1
D, while pregabalin-exposed infants had the same
ead circumference as those exposed to lamotrigine
Margulis et al., 2019). Other AEDs were not included in
he report. Data from the North American Antiepileptic
rug Pregnancy Registry (NAAPR), based on a selected
ohort of women with epilepsy, indicated that the
revalence of SGA was increased in infants exposed
o AEDs compared with unexposed infants (relative
isk [RR]: 2.0, 95% CI), and that the prevalence of
GA was particularly high (18.5%) for topiramate, but
lso increased with exposure to phenobarbital or zon-
samide (Hernandez-Diaz et al., 2017).
n association between exposure to an AED and
ntrauterine growth restriction does not necessarily
ean that there is a direct causal relationship. For
xample, an early study from Finland demonstrated499
genetic influence, indicating that head circumfer-
nce was smaller among fathers of the group of
ED-exposed children with small head circumference
Gaily et al., 1990).
he most consistent finding in these studies is the
rowth restriction associated with maternal use of
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opiramate. While the potential functional conse-
uences of this remain to be assessed, the findings
all for some caution in the use of topiramate during
regnancy when reasonable treatment alternatives are
vailable.
• Treatment with certain AEDs is associated with an
increased risk of intrauterine growth restriction.
• The effect on growth varies between different
AEDs and appears to be most pronounced with top-
iramate.
ajor congenital malformations
he first reports of an association between AEDs
nd congenital abnormalities were published more
han 50 years ago (Meadow, 1968). Research over
he years since 1968 has revealed that AEDs differ in
heir potential to cause MCMs. Two recent systematic
eviews agree that, for monotherapy, the highest risk
s associated with valproate and the lowest with lamot-
igine and levetiracetam exposure (Weston et al., 2016;
eroniki et al., 2017). Based on a network meta-analysis
Veroniki et al., 2017), the OR for MCM, relative to unex-
osed patients, was 2.93 for valproate (95% CI: 2.36-
.69), 1.90 for topiramate (95% CI: 1.17-2.97), 1.83 for
henobarbital (95% CI: 1.35-2.47), 1.67 for phenytoin
95% CI: 1.30-2.17), and 1.37 for carbamazepine (95% CI:
.10-1.71), while no increase was noted with lamotrig-
ne (OR: 0.96; 95% CI: 0.72-1.25) or levetiracetam (OR:
.72; 95% CI: 0.43-1.16). A Cochrane review (Weston
t al., 2016) reported similar results. Compared with
ffspring of women without epilepsy, the RR for val-
roate was 5.69 (95% CI: 3.33-9.73), topiramate was 3.69
95% CI: 1.36-10.07), phenobarbital was 2.84 (95% CI:
.57-5.13), phenytoin was 2.38 (95% CI: 1.12-5.03), and
arbamazepine was 2.01 (95% CI: 1.20-3.36). There was
o increased risk of MCMs with lamotrigine (Weston
t al., 2016). Gabapentin, levetiracetam, oxcarbazepine,
rimidone or zonisamide were not associated with
n increased risk, however, there were substantially
ewer data for these medications (Weston et al., 2016).
hile meta-analysis is a method to increase statisti-
al power, an important trade-off is the inclusion of
ata from heterogeneous studies, with different pop-
lations and even different criteria for MCMs (Veroniki
t al., 2017), both of which can significantly impact the
esults (Tomson et al., 2010). A comparison between00
reatments should therefore ideally be made within
ndividual studies. In this regard, prospective AED and
regnancy registries that have documented pregnan-
ies over 20 years have provided very useful data (Hunt
t al., 2008; Hernandez-Diaz et al., 2012; Mawhinney
t al., 2013; Campbell et al., 2014; Tomson et al., 2018).
he prevalence of MCMs for the most frequently used
l
h
d
c
a
a
l
EDs as monotherapy observed in the three major reg-
stries, the NAAPR, UK and Ireland Register, and EURAP,
re summarized in table 1. All three registries confirm
he greater risk with valproate and the comparatively
ow risk with lamotrigine and levetiracetam. Based on
he individual pregnancy registries, the risk of MCM
as analysed relative to dose. All registries revealed
ncreasing risks with higher doses of valproate, with
ut-offs for higher risks ranging from 500 mg/day based
n the NAAPR, to 600 mg/day and 650 mg/day based
n the UK-Ireland and EURAP registries, respectively.
ased on the EURAP, a dose-dependent effect was also
dentified for carbamazepine, lamotrigine and pheno-
arbital, whereas the UK-Ireland registry confirmed
ose-dependency for carbamazepine (Hernandez-
iaz et al., 2012; Campbell et al., 2014; Tomson et
l., 2018). Based on the EURAP, the lowest risk was
ssociated with lamotrigine at ≤325 mg/day at concep-
ion. In comparison, the prevalence of MCMs was
ignificantly higher at all doses of carbamazepine and
alproate. Valproate at doses as low as ≤650 mg/day
as also associated with an increased risk com-
ared with levetiracetam (OR: 2.43; 95% CI: 1.30-4.55)
Tomson et al., 2018).
olytherapy has traditionally been considered to be
ssociated with a higher risk of MCMs than monother-
py (Harden et al., 2009b; Veroniki et al., 2017).
owever, more recent studies indicate that the type of
ED included as polytherapy is more important than
he number of AEDs. When data from different reg-
stries on specific drug combinations were compared,
t was clear that inclusion of valproate as polytherapy
as the main reason for higher prevalence of MCMs
Morrow et al., 2006; Holmes et al., 2011). A recent
eport from the prospective Kerala Registry of Epilepsy
nd Pregnancy indicates that the excess MCM risk
ssociated with combination therapy with two AEDs
duotherapy) was largely dependent on the inclusion
f valproate or topiramate, in combination with one
ther AED (Keni et al., 2018). Based on the prospec-
ive EURAP, a comparison of MCM rates relative to
alproate monotherapy and duotherapy at different
ose levels of valproate revealed that a low dose of
alproate given in combination with another AED was
ssociated with lower MCM rates than a higher dose
f valproate as monotherapy (Tomson et al., 2015).
EDs also differ according to the type of MCM they are
ssociated with. A pooled analysis of 32 prospective
ohort studies revealed a particularly high preva-Epileptic Disord, Vol. 21, No. 6, December 2019
ence of cardiac malformations with barbiturates, and
igh prevalence of neural tube defects and hypospa-
ia with valproate (Tomson et al., 2016), which was
onfirmed in two recent meta-analyses (Weston et
l., 2016; Veroniki et al., 2017). Topiramate monother-
py has been associated with increased risk of cleft
ip/palate (de Jong et al., 2016; Veroniki et al., 2017,
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Table 1. Prevalence (%) of major congenital malformations (malformed/exposed) for different monotherapies.
Data from three prospective registers.
Drug International Registry of
Antiepileptic Drugs and
Pregnancy (EURAP)
North American AED
Pregnancy Registry
UK Epilepsy and
Pregnancy Register
Prevalence (95%CIs) Prevalence (95%CIs) Prevalence (95%CIs)
Carbamazepine 5.5 % (107/1,957) (4.5 - 6.6) 3.0% (31/1,033) (2.1 - 4.2) 2.6% (43/1,657) (1.9 - 3.5)
Lamotrigine 2.9% (74/2,514) (2.3 - 3.7) 1.9% (31/1,562) (1.4 - 2.8) 2.3% (49/2,098) (1.8 - 3.1)
Levetiracetam 2.8% (17/599) (1.7 - 4.5) 2.4% (11/450) (1.4 - 4.3) 0.7% (2/304) (0.2 - 2.4)
Oxcarbazepine 3.0% (10/333) (1.4 - 5.4) 2.2% (4/182) (0.9 - 5.5)
Phenobarbital 6.5% (19/294) (4.2 - 9.9) 5.5% (11/199) (3.1 - 9.6)
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Phenytoin 6.4% (8/125) (2.8 - 12.2) 2.
Topiramate 3.9% (6/152) (1.5 - 8.4) 4.
Valproate 10.3 % (142/1,381) (8.8 - 12.0) 9.
lotière et al., 2019), a risk that appears to be dose-
ependent (Hernandez-Diaz et al., 2018). Based on a
ecent nationwide cohort study utilizing French health
are databases, valproate was associated with eight
ifferent MCMs, whereas no significant association
ith any specific MCM was identified for lamotrig-
ne, levetiracetam, carbamazepine, oxcarbazepine, or
abapentin (Blotière et al., 2019).
he risk of MCM is also affected by other factors. Based
n the EURAP, parental history of MCMs was associ-
ted with a three-fold increase in risk (Tomson et al.,
018). Earlier studies indicate a high risk of MCMs in
he offspring from subsequent pregnancies in women
ho had previously given birth to a child with MCM,
uggesting individual susceptibility or a genetic pre-
isposition (Campbell et al., 2013; Vajda et al., 2013).
ased on the EURAP, changes in AED prescription
ere recently reported during pregnancy over a 14-
ear period (Tomson et al., 2019). In parallel with
ecreased use of valproate and carbamazepine and
ncreased prescription of lamotrigine and levetirac-
tam, the prevalence of MCMs declined by 27% over
he time period.
• Valproate is associated with the highest risk of
MCMs, phenobarbital and topiramate with an inter-pileptic Disord, Vol. 21, No. 6, December 2019
mediate risk, and lamotrigine and levetiracetam
with the lowest risk.
• The risk of MCMs is dose-dependent for valproate
and probably also for other AEDs such as carba-
mazepine, phenobarbital and lamotrigine
• For polytherapy, the type of AED included is at
least as important as the number of AEDs.
(
f
s
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2
a
m
2/416) (1.7 - 5.0) 3.7% (3/82) (1.2 - 10.2)
5/359) (2.5 - 6.8) 4.3% (3/70) (1.5 - 11.9)
0/323) (6.6 - 12.9) 6.7% (82/1,220) (5.4 - 8.3)
evelopmental and behavioural outcomes
oth animal and human studies demonstrate that pre-
atal exposure to valproate adversely affects foetal
rain development. Children exposed to valproate in
tero are at an increased risk of poorer development
n infancy (Bromley et al., 2010; Veiby et al., 2013a) and
educed IQ and other cognitive functions in preschool
ears (Meador et al., 2009; Cohen et al., 2011; Meador
t al., 2011). At school age, IQ is reduced by 7-11
Q points with abilities falling below average range
n 20-40% of valproate-exposed children (Nadebaum
t al., 2011; Meador et al., 2013; Bromley et al., 2014;
aker et al., 2015). Other key school-aged cognitive
kills, such as memory, attention and language skills,
ave also been found to be poorer in comparison to
ontrol children and children exposed to other AEDs
Nadebaum et al., 2011; Meador et al., 2013; Baker et al.,
015; Bromley et al., 2016). Not surprisingly, such cog-
itive deficits have been reported to lead to increased
ates of educational intervention, with reported levels
f need for 29-48% of exposed children across stud-
es for valproate monotherapy (Adab et al., 2001, 2004;
aker et al., 2015), with a dose-dependent influence
Baker et al., 2015). For children with clinically diag-
osed physical features of valproate embryopathy, the
eed for educational support is much higher, at 74%501
Moore et al., 2000; Bromley et al., 2019). Recent data
rom the Danish National Birth Cohort has demon-
trated poorer educational examination outcomes in
ate primary and early secondary school (Elkjaer et al.,
018) and an increase in learning disabilities (Bech et
l., 2018), highlighting the longer term and likely per-
anent valproate effects on cognition. Additionally,
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renatal exposure to valproate is associated with an
ncreased risk of autistic spectrum disorder diagnoses
Bromley et al., 2013; Christensen et al., 2013), atten-
ion deficit hyperactivity disorder (Adab et al., 2004;
ohen et al., 2011; Bromley et al., 2013; Christensen
t al., 2019), and other parent-rated behavioural prob-
ems (Huber-Mollema et al, 2019). These risks are
learly dose related although no dose of valproate
as been proven to be devoid of neurodevelopmental
isks, and doses of <400 mg/day have been associ-
ted with decreased verbal IQ and increased need
or educational assistance (Adab et al., 2004; Meador
t al., 2009, 2013; Bromley et al., 2014; Baker et al.,
015).
nvestigations of foetal carbamazepine exposure and
arly infant development have highlighted that devel-
pment levels are comparable overall to expected
rajectories for early infant development and school-
ged IQ (Bromley et al., 2014). School-age IQ is higher
n children with foetal carbamazepine exposure rel-
tive to foetal valproate exposure (Adab et al., 2004;
aily et al., 2004; Meador et al., 2011, 2013), and is
omparable to foetal lamotrigine exposure (Meador
t al., 2011, 2013) and that of control children (Rihtman
t al., 2013; Baker et al., 2015). However, there may
e risks associated with reduced verbal reasoning
kills (Meador et al., 2014; Baker et al., 2015). Children
ith foetal carbamazepine exposure were worse at
athematics in sixth grade compared with unexposed
ontrols, but the actual difference was small (Elkjaer et
l., 2018). Lower grades are consistent with an earlier
tudy in which a smaller number of children obtain-
ng high-level passes was documented (Forsberg et
l., 2011), however, the mechanism through which
uch an impact on education occurs remains unclear.
n earlier association with an increased risk of autis-
ic spectrum disorder among carbamazepine-exposed
ndividuals (Rasalam et al., 2005) has not been repli-
ated by a large national cohort (Christensen et al.,
013) or observational study (Bromley et al., 2013),
r based on parental ratings of symptoms of autis-
ic behaviours (Huber-Mollema et al., 2019). Increased
ehavioural problems have recently been reported in
iddle childhood (Huber-Mollema et al, 2019), how-
ver, only 14% of carbamazepine-exposed children
eached this clinical threshold which was based on
arental ratings.
hildren exposed to phenytoin in utero do not appear
o have poorer early developmental skills in infancy02
Wide et al., 2000b; Thomas et al., 2008; Bromley
t al., 2014), although this is in contrast to one
arly study (Scolnik et al., 1994). School-aged cohorts
xhibit expected IQ levels (Gaily et al., 1988; Meador
t al., 2009), but the data available are limited due
o the cohort size exposed to monotherapy. Chil-
ren exposed in utero to phenytoin are reported to
d
g
f
B
o
i
s
ave higher IQ than those exposed to valproate and
ave comparable IQ to groups exposed to carba-
azepine or lamotrigine (Meador et al., 2013; Bromley
t al., 2014). In terms of specific developmental out-
omes, one study highlighted poorer language skills
Rovet et al., 1995) whilst another noted poorer motor
evelopment (Wide et al., 2002), however, based on
he more recent NEAD study, poorer levels of lan-
uage or motor functioning were not documented
Meador et al., 2009, 2011, 2013; Cohen et al., 2011,
019). The relationship between phenytoin dose and
oorer neurodevelopmental outcome was investi-
ated, and no dose response was reported (Meador
t al., 2013).
arly development of infants exposed in utero to lam-
trigine has not been found to deviate from expected
rajectories (Bromley et al., 2010; Cummings et al., 2011)
nd has been demonstrated to be superior to chil-
ren exposed in utero to valproate (Meador et al.,
009). At school age, the NEAD study found that chil-
ren exposed in utero to lamotrigine were superior
n their IQ, memory and verbal skills compared to
oetal valproate exposure (Meador et al., 2013). IQ lev-
ls comparable to controls have been demonstrated
n two studies, but they were only powered to detect
arge levels of difference (Rihtman et al., 2013; Baker et
l., 2015). Children exposed in utero to lamotrigine had
omparable mathematics and Danish language exami-
ation results relative to control children (Elkjaer et al.,
018). In contrast, the Norwegian MoBa study reported
oorer language and social skills at 36 months based on
parental report for children exposed to lamotrigine
Veiby et al., 2013a). This has not been found by others
ased on direct child assessment (Bromley et al., 2010),
owever, relative verbal weakness vs. non-verbal skills
as identified in the NEAD study, although verbal skills
ere within normal range (Meador et al., 2013). Chil-
ren exposed to lamotrigine have not been found to be
t higher risk of autistic spectrum diagnoses (Bromley
t al., 2013; Christensen et al., 2013), but a recent study
eported an increase in certain behavioural outcomes
Huber-Mollema et al., 2019), however, a comparison to
n unexposed population was not undertaken in this
ater study.
he available data on the longer-term outcomes of
hildren exposed to levetiracetam in utero are pro-
ided by a UK study with a small sample size. In this
tudy, the children exposed to levetiracetam did not
iffer from control children in terms of their earlyEpileptic Disord, Vol. 21, No. 6, December 2019
evelopment and performed more strongly than the
roup exposed to valproate, with the same noted
or school-aged IQ (Shallcross et al., 2011, 2014;
romley et al., 2016). A dose-dependent effect was not
bserved at any age, but extension of these results
nto larger prospective cohorts is required. In one
tudy on behavioural outcomes, an increase in certain
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ehavioural problems was reported for children (mean
ge: 6.5 years), as rated by parents, (Huber-Mollema
t al, 2019), however, this requires further investiga-
ion as there was no direct comparison to a control
roup.
amotrigine and levetiracetam have become the most
ommonly used AEDs in pregnancy in tertiary epilepsy
entres in the USA (Meador et al., 2018) and other
ountries (Kinney et al., 2018). However, data for
ven these two AEDs are inadequate. The size of
ohorts and the outcomes investigated are small, and
onsideration should be given to the variable rela-
ionship between prescribed dose and serum blood
evels (Johannessen Landmark et al., 2017). Both lam-
trigine and levetiracetam exhibit marked changes in
etabolism during pregnancy, which can alter foetal
xposure, and no study has adjusted for changes in
ED blood levels during pregnancy.
ur understanding of the potential impact of other
EDs on the developing brain is almost non-existent.
hilst two studies have investigated topiramate expo-
ure in utero, both were small with conflicting findings
Rihtman et al., 2012; Bromley et al., 2016). For oxcar-
azepine, no association with an increased risk of
utistic spectrum diagnosis was found (Christensen
t al., 2013) and examination performance did not
iffer relative to controls, with the exception of
ixth-grade mathematics, although the magnitude
f difference was reportedly small (Elkjaer et al.,
018). Other studies contained sample sizes that were
oo small to provide reliable information on other
eurodevelopmental outcomes associated with oxcar-
azepine. No reliable data are currently available for
ther AEDs.
reastfeeding has proven beneficial for both the
other and child (Ip et al., 2009). Some have raised
oncerns over breastfeeding when taking an AED.
owever, this concern has not been upheld. The
EAD study and a Norwegian study found no adverse
eurodevelopmental effects in children at age three
ears old who were breastfed by mothers on AEDs,
nd in the NEAD study, children who were breastfed
ad higher IQ levels at six years of age com-
ared to children of mothers with epilepsy who
ere not breastfed (Meador et al., 2010, 2014; Veiby
t al., 2013b).
espite the potential detrimental and lifelong impact
n brain development, clear replicated data for the
ajority of currently prescribed AEDs are lacking.
arger cohorts with investigation of a dose-dependent,pileptic Disord, Vol. 21, No. 6, December 2019
r even better, blood concentration-dependent influ-
nce on outcomes are required. Care should be taken
o ensure that a lack of evidence of harm is not taken
s evidence of safety, and risk-benefit discussions with
atients about their treatment should reflect what is
nown and additionally, what is not known, about
c
2
r
s
b
d
Management of epilepsy in pregnancy
eurodevelopmental outcomes associated with indi-
idual AED treatments.
• Exposure in the womb to valproate carries a sig-
nificant dose-dependent risk associated with child
cognition and neurodevelopmental disorders (e.g.
autistic spectrum disorder).
• Carbamazepine does not appear to be a major
neurobehavioural teratogen.
• Current data regarding lamotrigine suggest
comparable IQ to control children.
• There are limited data pertaining to levetiracetam,
topiramate and other AEDs in terms of later child
cognition.
eizure control during pregnancy
he seizure burden remains unchanged during preg-
ancy for about two thirds of women (Thomas et al.,
012; Battino et al., 2013). In the prospective observa-
ional EURAP study, 67% of women were seizure-free
hroughout pregnancy (Battino et al., 2013). The period
f pregnancy with the highest incidence of seizures is
abour and delivery, but this occurs in no more than
-2% of pregnancies in women with epilepsy (Battino
t al., 2013).
he occurrence of seizures before pregnancy is the
ost important predictor of seizures during preg-
ancy (Thomas et al., 2012). Women who experienced
eizures in the month prior to pregnancy had a 15-
old greater risk of seizures during pregnancy (Thomas
t al., 2012). Conversely, more than 80% of women
ho were seizure-free the year before conception,
emained so throughout pregnancy (Vajda et al., 2008).
he impact of a specific pattern of seizures before
regnancy on the course during pregnancy has been
nvestigated in a prospective follow-up of seizure
ourse in women with catamenial epilepsy and women
ith non-catamenial epilepsy (Cagnetti et al., 2014).
eizure control was improved during pregnancy in the
atamenial group; 44.1% experienced a ≥50% reduc-
ion in seizures, whereas only 6.5% of those with
on-catamenial epilepsy had a similar reduction in
eizures.
ther general predictors of seizure worsening dur-
ng pregnancy are focal epilepsy syndromes, the need
or polytherapy, and decreased serum levels of AEDs503
ompared to preconception baseline (Reisinger et al.,
013). The clearance of newer AEDs, such as lamot-
igine, levetiracetam, and oxcarbazepine, is increased
ignificantly during pregnancy which may result in
reak-through seizures related to lower serum levels if
osages are not adjusted (Pennell et al., 2008; Voinescu
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t al., 2018). This is discussed in more detail in the
ollowing section.
ther factors that may predispose to seizure
ggravation during pregnancy include anxiety, non-
dherence to medication, sleep deprivation, and
ifficulty in retaining orally administered AEDs due to
omiting.
ppropriate counselling can help to alleviate the stress
actors and improve drug therapy adherence, which is
n line with the observation that women with planned
regnancies have a lower frequency of seizures during
regnancy (Abe et al., 2014).
tatus epilepticus was reported in only 0.6% of all
regnancies in the EURAP study (Battino et al., 2013);
f these, 10 were convulsive, and cases were evenly
istributed over the three trimesters. Perinatal death
ccurred in one of the pregnancies of women experi-
ncing a convulsive status epilepticus, and none of the
others died.
• Most women with epilepsy maintain their seizure
control during pregnancy.
• Pre-pregnancy seizure control is the most impor-
tant predictor of seizure control during pregnancy.
• Non-adherence to AED medication and alter-
ations in AED clearance are major causes of
break-through seizures.
harmacokinetic changes during
regnancy
challenge in managing epilepsy during preg-
ancy is the pronounced pharmacokinetic alterations,
ncluding altered absorption, increased volume of dis-
ribution, elevated renal excretion, and induction of
epatic metabolism. AED clearance is a term that can
ccount for all these changes, and is calculated as
ollows:
learance = AED dose (mg/kg/day) / AED concentration
nowledge about the pattern of gestational age-
ependent clearance changes can help guide the
iming and range of AED dose adjustments and
ontribute to maintaining seizure stability during preg-
ancy.
amotrigine is the most studied AED with regards
o clearance changes during pregnancy, with find-04
ngs of markedly increased clearance during preg-
ancy (Pennell et al., 2008; Harden et al., 2009a;
ennell, 2013; Tomson et al., 2013), likely mainly
ue to oestrogen-driven enhanced glucuronidation
uring pregnancy. Additionally, substantial inter-
ndividual variability was noted in most of these
tudies. A formal pharmacokinetic modelling analysis
l
p
e
H
m
r
w
emonstrated two subpopulations, one with 23% of
omen who had only a 20% increase in lamotrig-
ne clearance and another with 77% of women who
ad a 220% increase in clearance, hypothesized to be
ue to pharmacogenetic differences (Polepally et al.,
014). A recent study with frequent sampling, begin-
ing prior to pregnancy and through the first trimester,
ighlighted that clearance changes are measurable as
arly as the third week after conception and clear-
nce increases by an average of 50% by the end of
he first trimester (Karanam et al., 2018). These findings
nderscore the importance of performing therapeutic
rug monitoring when available and beginning early
n pregnancy.
tudies of other AEDs have demonstrated changes
n clearance during pregnancy which vary accord-
ng to the pathway of drug elimination (table 2).
or example, early and substantial glomerular fil-
ration rate and renal blood flow increase during
regnancy as well as studies on levetiracetam have
emonstrated similar changes in clearance (Tomson
t al., 2007; Westin et al., 2008; Lopez-Fraile et al.,
009). A larger and prospective study demonstrated
hat the increase in clearance is maximal in the first
rimester, with a 71% increase above non-pregnant
aseline (n=18 pregnancies) (Voinescu et al., 2018).
n contrast, studies on carbamazepine report little
hange in total carbamazepine clearance during preg-
ancy and no significant change in free carbamazepine
r free carbamazepine-10, 11-epoxide concentrations
Johnson et al., 2014).
he clinical importance of the changes in AED clear-
nce has been demonstrated in a few studies. In one
arly study with lamotrigine (Pennell et al., 2008); pre-
onception clinical data were used to determine an
ndividualized target concentration; the ratio-to-target
oncentration (RTC) was calculated for each blood
raw during pregnancy and an RTC threshold of 0.65
as identified as a significant predictor of seizure
orsening in the second trimester. Two other stud-
es have reported that this same rule applies to other
EDs, demonstrating that when the AED concentra-
ion decreases to 65% or less of the individual target
oncentration, the risk of seizure worsening increases
Harden et al., 2009a; Reisinger et al., 2013; Voinescu et
l., 2018).
uring the postpartum period, AED clearances return
o non-pregnant baseline, but studies delineating the
ate of these changes are limited. An empiric taper of
amotrigine over 10 days to pre-pregnancy baseline
lus 50 mg resulted in low rates of lamotrigine sideEpileptic Disord, Vol. 21, No. 6, December 2019
ffects and seizure worsening (Pennell et al., 2008).
owever, based on the only formal pharmacokinetic
odelling study of lamotrigine to date, clearance was
eported at non-pregnant baseline level over three
eeks (Polepally et al., 2014).
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Table 2. Summary of individual antiepileptic drug projected decreases in serum concentrations
(if no dose changes are made).
AED Decrease in serum
concentration
Decrease in serum free
(unbound) concentration
Recommendations to perform
therapeutic drug monitoring, if
available
Phenobarbital Up to 55% Up to 50% Yes
Phenytoin 60 - 70% 20 - 40% Yes, free concentration
Carbamazepine 0 - 12% None Optional
Valproate Up to 23% None Optional, free concentration if
done
Oxcarbazepine
monohydroxy-derivative
(MHD)
36 - 62% N/A Yes
Lamotrigine 0.77 of population: 69%
decrease
0.23 of population: 17%
decrease
N/A Yes
Gabapentin Insufficient data N/A Yes
Topiramate Up to 30% N/A Yes
Levetiracetam 40 - 60%, with maximal
decrease reached in first
trimester
N/A Yes
Zonisamide Up to 35% but little data N/A
N/A: not applicable.
• Pregnancy can have a major impact on the phar-
macokinetics of antiepileptic drugs.
• The most marked decline in serum concentra-
tion during pregnancy is seen with lamotrigine,
levetiracetam, and oxcarbazepine, but phenobar-
bital, phenytoin, topiramate, and zonisamide also
undergo a clinically relevant increase in elimination.
• A decline in serum concentration by >35% from
a pre-pregnancy optimal concentration is associ-
ated with increased risk of deterioration in seizure
O
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u
planning the pregnancy should therefore be broughtcontrol.
• The extent to which pregnancy affects AED blood
levels varies between individual women and is best
controlled by blood level sampling.
ptimal management before pregnancypileptic Disord, Vol. 21, No. 6, December 2019
reconception care
reconception care and planning the pregnancy ahead
an help to improve the outcome of pregnancy in
omen with epilepsy. In a study from the UK, women
u
w
T
e
(
t
Yes
ho had proactive counselling prior to pregnancy
ere more likely to be on monotherapy and on
EDs other than valproate, and the prevalence of
CM in their offspring was lower (Betts and Fox,
999). Preconception planning and care has also been
hown to be associated with improved seizure control
nd reduced AED burden during pregnancy (Abe et
l., 2014). Surveys among women with epilepsy who
ere considering pregnancy revealed that they did
ot receive sufficient information on pregnancy and
pilepsy (Crawford and Hudson, 2003; McGrath et al.,
014). One major challenge in provision of adequate
re-conception counselling is unplanned pregnan-
ies. In a recent study from the US, approximately
5% of pregnancies in women with epilepsy were
nplanned (Herzog et al., 2017). The importance of505
p regularly in each routine consultation with women
ith epilepsy with childbearing potential.
he standards of preconception care for women with
pilepsy have been discussed and reviewed in the past
Kinney and Morrow, 2016). A protocol for preconcep-
ion care is provided in table 3. This is the period in
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hich to reconsider the indication for, and the choice
f AED treatment. If a change in medication is consi-
ered, it should be completed early enough to allow
ufficient time to assess the effectiveness of the new
egime before conception. This could mean that an
ttempt to change may need to be initiated as early as
ne year before a planned pregnancy. The objective of
he treatment review and possible revision is to estab-
ish, before conception, the lowest effective dose of
he appropriate AED for an individual woman, and to
ocument the associated drug serum concentration,
hen possible.
olate
t is also important that adequate folate supplemen-
ation is initiated in the preconception stage. The US
egulatory authorities recommend 0.4 mg of folic acid
or all women with child bearing potential and a higher
ose of 4 mg daily for women with a higher risk, such
s those with past pregnancies involving neural tube
efect or anencephaly (Centers for Disease Control,
992). A higher dose of folate at 4 mg was associ-
ted with a lower risk of recurrent neural tube defects
ased on a randomized controlled trial, in which
omen with epilepsy were excluded (MRC Vitamin
tudy Research Group, 1991). In the general popula-
ion, folate supplementation has been associated with
educed cardiac malformations (Czeizel et al., 2013).
here are also several studies in the general population
howing positive effects of folate supplementation on
eurodevelopmental and behavioural outcomes, but
his effect remains controversial (Wehby and Murray,
008; Julvez et al., 2009; Roza et al., 2010; Schlotz et al.,
010; Roth et al., 2011; Chatzi et al., 2012; Skorka et al.,
012; Villamor et al., 2012). Despite the fact that some
EDs interfere with folate, data on the effects of folate
upplementation on pregnancy outcomes in women
reated for epilepsy are not conclusive. Reports from
he prospective epilepsy pregnancy registries have
ailed to demonstrate that periconceptional use of
olate is associated with a lower risk of MCMs (Morrow
t al., 2009; Tomson et al., 2018). The NEAD study found
mproved IQ scores in six-year-old children of women
ith epilepsy who began folate prior to conception
nd in early pregnancy (Meador et al., 2013). In a related
K study, folate supplementation was not found to
e associated with increased IQ scores (Baker et al.,
015). In the Norwegian MoBa study, folate supple-08
entation and higher plasma concentration of folate
arly in pregnancy were associated with a reduced
isk of autism symptoms at three years of age in chil-
ren of women taking AEDs, as rated by the mothers
Bjork et al., 2018). Further, data from the Norwegian
oBa study also highlighted a reduction in language
elay in children receiving folate supplementation in
t
f
s
(
I
s
a
omparison to those not taking folate (Husebye et al.,
018). It should be noted that the observational cohort
tudies (Morrow et al., 2009; Meador et al., 2013; Baker
t al., 2015; Tomson et al., 2018) were not primarily
esigned to assess the effects of folate supplemen-
ation. Hence, presence or absence of an association
oes not prove or exclude a beneficial effect of
olate supplementation on AED-induced adverse preg-
ancy outcomes. Unfortunately, the available data
rom women with epilepsy provide limited guidance
egarding adequate dose of folate. Clearly, women
ith epilepsy should be prescribed at least 0.4 mg/day
ince this is the recommended dose for women in gen-
ral, as well as women with epilepsy according to some
uidelines (Harden et al., 2009a). The fact that some
EDs can interfere with folate suggests that higher
oses of folate might be required, but there have been
oncerns that folate, in particular at high dose, may
ncrease the risk of cancer, cognitive impairment, and
ral clefts (Frankenburg, 2009; Rozendaal et al., 2013;
orris et al., 2010; Murray et al., 2018). Some guide-
ines recommended that all women with epilepsy who
re trying for pregnancy should start on folic acid at
mg daily, at least three months prior to pregnancy, and
ontinue with the same dose throughout pregnancy
Wilson et al., 2007; NICE, 2012), however, evidence for
n optimal periconceptional dose of folate in women
ith epilepsy taking AEDs remains inadequate. Given
he incidence of unplanned pregnancies, women with
hildbearing potential taking AEDs should also be on
olate, at least 0.4 mg/day.
ptimal management during
regnancy, delivery and postpartum
or recommended management strategies during
regnancy, delivery, and early postpartum, see table 3.
nce pregnancy occurs, it is important to quickly
stablish detailed coordinated care between the neu-
ologist, obstetrician, and the patient. Since such a
arge percentage of women will have unplanned preg-
ancies, the first visit often needs to incorporate
lements of preconception care, if not already done
o. Regardless, it is ideal to schedule the first preg-
ancy visit early within the first trimester to ensure
hat supplementary folic acid is being taken. The physi-
ian should re-evaluate the AED dose if not done
ecently. Counselling of the patient should reinforceEpileptic Disord, Vol. 21, No. 6, December 2019
he need for AEDs, and any potential AED risk to the
oetus should be balanced against the risk of increased
eizures to both the mother and the developing foetus
see Maternal and foetal risks associated with seizures).
f the woman is taking an AED that undergoes sub-
tantial clearance changes (table 2) and if drug levels
re obtainable, it is ideal to determine a blood level
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y the mid first trimester given the early gestational
hanges during clearance that occur for many of the
ommon AEDs used during pregnancy (Karanam et al.,
018; Voinescu et al., 2018). The individualized target
oncentration should be reassessed and maintained
uring pregnancy with blood levels throughout preg-
ancy (Harden et al., 2009a). The need for follow-up
rug level monitoring will depend on the type of AED
less important for some AEDs with minor changes dur-
ng pregnancy, see table 2) as well as each woman’s
ensitivity to alterations in drug levels before preg-
ancy and her type of epilepsy. Many experts in the
eld obtain levels every four weeks for AEDs when
ajor changes occur (e.g. for lamotrigine, levetirac-
tam, oxcarbazepine, phenobarbital, phenytoin, and
onisamide), with additional checks if clinically indi-
ated by seizure frequency changes or medication side
ffects or concerns about medication adherence. The
oal is to adjust the AED dosing to maintain the specific
arget concentration(s) for each woman with epilepsy,
iven that the risk of seizure worsening increases if
he level decreases by 35% or more from the baseline,
on-pregnant target concentration (Pennell et al., 2008;
eisinger et al., 2013; Voinescu et al., 2018).
f AED blood levels are not available, then it is rea-
onable to consider an increase in dose after the first
rimester, at least in women whose epilepsy includes
TCS, that were sensitive to changes in AED levels
efore pregnancy, and who entered pregnancy on
he lowest effective dose of their medication, pro-
iding they are treated with AEDs that are known
o undergo marked changes during clearance (lam-
trigine, levetiracetam, and oxcarbazepine). There is
o evidence to guide how this should be done best,
nd the issue is further complicated by the fact that
he timing and extent to which AED levels decline
aries considerably between women. A precautionary
pproach would be to increase the dose by 30-50%,
hich in most cases is less than required to main-
ain the target concentration, while avoiding exposure
f the foetus to unnecessarily high AED levels in the
ew mothers whose serum levels decline less on aver-
ge. If a woman has a break-through GTCS, a dose
ncrease should be strongly considered, especially
f convulsions were previously controlled and if the
oman is taking an AED with known marked clearance
hanges during pregnancy. An increase in other kinds
f seizures (e.g. focal aware seizures, focal impaired
wareness seizures, or JME myoclonic seizures) shouldpileptic Disord, Vol. 21, No. 6, December 2019
lso prompt consideration of dose increase.
f the woman is experiencing nausea and emesis, coun-
elling should include strategies to re-dose if emesis
ccurs shortly after ingestion of her dose. It can be
elpful to communicate with the obstetrician for rec-
mmendations to reduce emesis if it is interfering with
aintaining AED steady-state concentrations.
A
v
D
a
p
i
n
Management of epilepsy in pregnancy
atients with epilepsy have higher rates of depression
nd anxiety than the general population, and this is
lso the case during pregnancy and the postpartum
eriod. Studies have indicated especially higher rates
f postpartum depression in women with epilepsy, and
hese symptoms often begin intrapartum (Turner et
l., 2006; Galanti et al., 2009). Ideally, management of
omen with epilepsy should incorporate screening for
epression and anxiety, especially during pregnancy
nd postpartum.
n settings where prenatal testing is available and
cceptable, usual testing for all women will include
rst-trimester Down syndrome screening in the late
rst trimester, between 9-14 weeks gestational age,
ith combined measurements of serum beta-hCG and
erum pregnancy associated plasma protein (PAPP-A),
n ultrasound measurement of nuchal translucency,
nd consideration of maternal age to provide patient-
pecific risk (Pennell and McElrath, 2019). These tests
lso provide confirmation of gestational age and
he potential to detect some severe MCMs early.
owever, a more definitive structural ultrasound
ill be performed at 18-22 weeks of gestation; in
omen with epilepsy, it is ideal to obtain a detailed
specialized) foetal structural survey by a trained
pecialist. Foetal echocardiography is not necessary
s a routine measure, but only if there is a clini-
al indication. If there is a concern for intra-uterine
rowth retardation, then serial ultrasounds may be
erformed.
he third trimester is a critical time to coordinate
ecommendations for labour and delivery and early
ostpartum care between the neurologist and obste-
rician, with consideration of the patient’s desired birth
lan. If prenatal screening has indicated anticipated
ewborn problems, the neonatology team should also
e included in the planning phase. The diagnosis of
pilepsy itself is not an indication for Caesarean sec-
ion. Seizures and their treatment during labour and
elivery may interfere with the patient’s ability to par-
icipate in active labour, however, this occurs only
arely. Seizures during labour and delivery are best
reated with the usual rescue therapy using a low dose
f a quick-acting benzodiazepine. Vaginal deliveries
re the norm. The benefits of pain management with
pidural anaesthesia are the same for women with
pilepsy as for any other women, and include reducing
he duration of intense pain and maximal stress, and
acilitating some rest prior to the active stage of labour.
t delivery, all children should routinely receive 1 mg509
itamin K IM.
iscussion during the late third trimester should
lso include possible increased seizure worsening
eripartum, desires and strategies for breastfeed-
ng, strategies to lessen prolonged sleep deprivation,
ewborn safety, and a plan to adjust AED dosing post-
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myoclonic epilepsy. She first sought medical advice. Tomson, et al.
artum if increases have been made during pregnancy
Voinescu and Pennell, 2017).
f AED dosing has been increased during pregnancy,
he rate of taper of AEDs back to pre-pregnancy dose or
lightly above depends mainly on the primary route of
limination for each individual AED. The physiological
hanges of renal and some hepatic enzymatic func-
ions (e.g. glucuronidation) associated with pregnancy
ill rapidly resolve over the first two to three weeks
ostpartum, while other hepatic enzymes (many of
he cytochrome P450 enzymes) may take one to two
onths to return to baseline clearance rates (Yerby et
l., 1990, 1992). Postpartum AED tapers are prescribed
mpirically, as a steady-state level is not obtainable
ith the rapid changes during clearance, and it often
akes a few days to obtain results for most of the
econd- and third-generation AEDs at most clinical
entres (see section on Pharmacokinetic changes dur-
ng pregnancy).
iven the benefits of breastfeeding with regards
o both short- and long-term neonatal health in
he general population (http://www.who.int/topics/
reastfeeding/en/), and the data from studies show-
ng no adverse neuropsychological effects in children
f mothers taking AEDs, breastfeeding should in gen-
ral be encouraged. Treatment should be adapted
ccording to how sensitive their seizures are to
leep deprivation based upon their history and their
pilepsy syndrome. However, the risk of seizures
n the postpartum period relative to specific sleep
atterns has not been addressed in high-quality
tudies.
he risk of seizures may be increased in the post-
artum period, sometimes for several months, due to
leep deprivation. Couples and other family members
hould be counselled, ideally as a function of prenatal
are, to make arrangements in order to allow ade-
uate sleep while caring for a newborn. Some families
dopt a “shift” approach so the mother can reliably
btain uninterrupted and regular nightly sleep. Addi-
ionally, even if the mother has been seizure-free for a
ong time, she should take a more conservative safety
pproach until she achieves regular sleep again, given
hat sleep deprivation is a strong provoker of many
eizure types.
ommon sense safety considerations during the new-
orn period should be discussed and reinforced; these
nclude no driving, no bathing of the baby with the
other alone, and no co-sleeping with the mother in
he parents’ bed. If the mother is at risk of myoclonic
eizures, then a baby carrier (sling or harness) should
e used when walking around with the baby. In the10
arly postpartum period, the mother should also be
iscouraged from taking a bath by herself behind
closed, locked door or when no other adult is
round.
a
o
s
h
onclusions
he challenge in the management of epilepsy during
regnancy is to balance the foetal and maternal risks
ssociated with seizures against the teratogenic risks
ssociated with exposure to AEDs in utero. Address-
ng issues related to pregnancy should begin well
efore conception in order to maximize pregnancy
utcomes. It is clear that AEDs differ in their ter-
togenic potential. Valproate is associated with the
reatest risk of malformations as well as adverse cogni-
ive and behavioural outcomes, and should, whenever
ossible, be avoided for the treatment of patients who
ay become pregnant. Lamotrigine and levetiracetam
re associated with the lowest risk of malformations,
ut data on neurodevelopment for levetiracetam is
ased on a small sample and evidence on the effects
f prenatal exposure on neurodevelopment is lack-
ng or insufficient for other newer-generation AEDs.
eratogenic risks should be considered at the time of
nitiation of AED treatment in young female patients.
re-pregnancy counselling is essential to ensure that
he woman enters pregnancy on the most appropriate
ED treatment, taking efficacy as well as foetal safety
nto account, and that she is also taking folate sup-
lementation. Once pregnancy is established, close
onitoring is warranted and ideally in collaboration
etween epilepsy and obstetric care.
t should finally be emphasized that the vast majority
f women with epilepsy will have uneventful pregnan-
ies and give birth to healthy children. The aim of the
ecommendations in this review is to further facilitate
uch positive pregnancy outcomes.
ase studies and discussion
ase 1
hristina is 27 years old. She has had epilepsy for
wo years with focal seizures with impaired awareness;
efore she was started on treatment, she had had a
ingle focal to bilateral tonic-clonic seizure. MRI was
egative. She was initiated on lamotrigine and became
eizure-free a year ago after a gradual increase in the
amotrigine dose to 250 mg/day. She is considering
regnancy.
ase 2
ara is 18 years old with newly diagnosed juvenileEpileptic Disord, Vol. 21, No. 6, December 2019
fter her second tonic-clonic seizure. Her first seizure
ccurred after a party night whereas the second
eemed unprovoked. In retrospect, it is clear that she
as had myoclonic seizures every month for a year.
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ase 3
udy is a 25-year-old woman who has had juvenile
yoclonic epilepsy for seven years. The first medica-
ion that she tried was levetiracetam. She continued to
ave tonic-clonic seizures at a dose of 1,500 mg/day.
igher doses induced intolerable psychiatric side
ffects. She was therefore switched to valproate five
ears ago and became seizure-free when the dose
as increased to 900 mg/day. She has now discovered
hat she is pregnant at Gestational Week 7, which was
nplanned.
ase 4
iranda is a 25-year-old woman who has juvenile
yoclonic epilepsy which was diagnosed at the age
f 16. She was first tried on lamotrigine but continued
o have tonic-clonic seizures despite a maximum toler-
ted dose of 400 mg/day. Levetiracetam was added to
amotrigine but seizures continued. Lamotrigine was
apered while the levetiracetam dose was increased
radually up to 3,000 mg/day, a dose at which she
xperienced intolerable mood changes and contin-
ed seizures. Having failed two different drugs at
he highest tolerable doses, she was switched from
evetiracetam to valproate. She continued to have
ccasional tonic-clonic seizures until the dose was
ncreased to 800 mg/day (400 mg BID), after which
he has been seizure-free for the last three years. She
as a boyfriend but no immediate plans to become
regnant.
ases related to preconception management
n the first case, Christina has focal impaired aware-
ess seizures and rare bilateral tonic-clonic seizures
hat had responded well to a moderate dose of lamot-
igine. The pre-conception care in this instance would
ocus more on optimal AED usage to maintain seizure
reedom during pregnancy and minimise the risk of
oetal complications. Ascertaining the blood level of
amotrigine in the preconception stage and institut-
ng folate supplementation at this stage are part of the
re-conception care.
he second case, Sara is in a situation where initiation
f AED treatment is justified. Given that she is likely
o continue with her treatment for many years, the
fficacy as well as the teratogenic potential needs topileptic Disord, Vol. 21, No. 6, December 2019
e considered when deciding on her treatment. While
alproate is likely to be the most effective AED for her
pilepsy, this drug should be avoided whenever pos-
ible in this patient population. The most reasonable
rst-line options are therefore levetiracetam or lamot-
igine. Where available, a trough serum concentration
hould be obtained prior to pregnancy to establish
r
c
b
r
s
f
p
Management of epilepsy in pregnancy
er target concentration; this concentration should be
aintained during pregnancy, and a decrease by 35%
r more should be avoided in order to reduce the risk
f seizure worsening.
he fourth case, Miranda, is on treatment with val-
roate after having failed on two other AEDs as
onotherapy as well as one combination treatment.
iven the known risks to the foetus associated with
xposure to valproate, regulators have issued restric-
ion on its use in women with childbearing potential.
ccording to the FDA, valproate should not be admin-
stered to a woman with childbearing potential unless
ther medications have failed to provide adequate
ymptom control or are otherwise unacceptable. In
uch situations, effective contraception should be
sed (FDA, 2017). The European Medicines Agency
EMA) considers valproate contraindicated in women
ith childbearing potential unless the conditions of
he pregnancy prevention programme are fulfilled
European Medicines and Agency, 2018). The latter
s a detailed list of requirements, including effective
ontraception, but also includes a key element relating
o information for the woman on the risks of congeni-
al malformations and neurodevelopmental disorders
ncluding the magnitude of these risks.
iranda should be informed that her current medi-
ation is associated with a 7-10% risk of MCM in the
ffspring as well as a significant risk of reduced IQ (e.g.
-10 IQ points) and other cognitive and behavioural
e.g. five-fold increased risk of autism) impairments,
hould she become pregnant on valproate. The risk
f poorly controlled epilepsy needs to be balanced
gainst teratogenic risks associated with valproate.
nother element in the pregnancy prevention pro-
ramme is to make sure that the patient understands
he need to consult her physician as soon as she is
lanning pregnancy to ensure timely discussion and
witching to alternative treatment options prior to
onception and before contraception is discontinued
ince valproate is considered contraindicated in preg-
ancy unless there is no suitable alternative treatment
European Medicines and Agency, 2018).
major concern has been inadequate informed con-
ent for many women on valproate. Miranda needs
etailed current information on the risks and poten-
ial benefits of all possible treatment options in order
o make a shared informed decision. Depending
n her personal situation, she might prefer not to
isk loss of seizure control with treatment changes
ight now, or at all, or she could opt for such511
hanges as soon as possible. Regardless, she should
e recommended folate supplementation. The EMA
ecommends dividing the valproate daily dose into
everal doses over a day and/or use of extended release
ormulations if valproate is going to be used during
regnancy, but there are no clinical data showing that
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H, Yoshikawa H. Impact of planning of pregnancy in women
with epilepsy on seizure control during pregnancy and on. Tomson, et al.
his approach reduces teratogenic risks (Mawhinney
t al., 2012).
alf of pregnancies are not planned, thus scheduling
iscussion once a pregnancy is planned will be too late
or many pregnancies. Women should be informed of
isk at the time of valproate prescription. Given the
isk of unplanned pregnancy, Miranda may prefer to
onsider treatment alternatives at this stage. She has
lready failed the two most reasonable alternatives,
nd also tried the lowest effective dose of valproate.
herefore, established suitable alternatives have been
ried without acceptable seizure control. Other possi-
le alternatives beyond lamotrigine and levetiracetam
nclude zonisamide and topiramate. Both have lim-
ted documentation regarding effectiveness for JME,
s well as safety in pregnancy. While the limited data
n zonisamide do not signal an increased risk of
CMs, no data on the effects of foetal zonisamide
xposure on neurodevelopment are available. Topira-
ate appears to be associated with an intermediate
isk of MCMs (about 4.5%), and limited data in ani-
als and humans suggest that it does not have major
eurodevelopmental effects. There are essentially no
ata on pregnancy safety for other AEDs which are
ffective for generalized epilepsy (e.g. perampanel).
f valproate cannot be avoided, one option may be
o consider a decrease in valproate with addition of
amotrigine.
ase related to management during pregnancy
onsidering our third case, Judy is already pregnant.
he data discussed in previous sections highlight that
here are increased risks regarding aspects of neurode-
elopment and physical malformations associated with
alproate treatment. Most of the period when malfor-
ations are more likely to occur has already passed,
nd treatment modification will not reduce these risks.
owever, in contrast, valproate exposure throughout
regnancy may have an impact on neurodevelopment.
mportantly, these adverse effects have been found
o be dose-dependent. Her dose of 900 mg/d is on
he low side, with the evidence to date demonstrat-
ng increased risks over 800-1,000 mg/d, but there are
till risks noted at doses <800 mg/d (Baker et al.,
015). Switching her AED during pregnancy will lead
o a period of polytherapy. If an attempt is made
o switch to lamotrigine, the transition period with
olytherapy may require 7-8 weeks in order to mini-12
ize the risk of idiosyncratic reactions. Given Judy’s
revious trial of other AEDs, a switch from, or with-
rawal of valproate may lead to suboptimal control
f her epilepsy. It is therefore of paramount impor-
ance that Judy is counselled carefully in order to
iscuss the risks of treatment and the optimisation of
er health. Withdrawal of, or switch from valproate at
m
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his stage of pregnancy is associated with a significant
isk of GTCSs with potential harm to the mother and
oetus, with uncertain neurodevelopmental effects.
his is an unfortunate situation that hopefully can
e avoided with pregnancy planning, proactive pre-
regnancy counselling, consideration of AED changes
rior to pregnancy, and use of valproate in women
ith childbearing potential only when absolutely
ecessary. 
upplementary data.
ummary didactic slides are available on the
ww.epilepticdisorders.com website.
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EDUCATION
(1) What is the risk of major congenital malformations in offspring after maternal use of valproate?
(2) Why is it important for women with epilepsy taking AEDs to also take periconceptional folate?
(3) Serum concentrations of many antiepileptic drugs tend to decrease during pregnancy. What level of
decrease is associated with a significant risk of deterioration in seizure control?
(4) Provide the 2 most frequent causes of breakthrough seizures during pregnancy.
(5) Which of the statements below are not true:
A. During the newborn period bathing of the baby with the mother alone should be avoided.
B. During the newborn period the mother should priviliege using a baby carrier when walking around with
the baby;
C. Breastfeeding should be prohibited
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D. In the early postpartum period, the mother should also
a closed, locked door or when no other adult is aroun
Note: Reading the manuscript provides an answer to all q
website, www.epilepticdisorders.com, under the section517
be discouraged from taking a bath by herself behind
d.
uestions. Correct answers may be accessed on the
“The EpiCentre”.
